WAY-316606: The Osteoporosis Compound Tested Against Hair Loss

Facebook ↗WhatsApp ↗

Originally published 2018-05-19.

Alopecia Research Involving a Drug's Effects on Hair Follicles

Docent/Shutterstock

In May 2018, scientists at the University of Manchester reported that a compound called WAY-316606, first developed as a possible osteoporosis treatment, made human scalp hair follicles grow faster in the laboratory. It works by blocking a protein called SFRP1 that acts as a brake on hair growth. The finding came from studying why an old transplant drug, cyclosporine A, sometimes causes unwanted hair growth.

The short answer for anyone with thinning hair: this is a promising lead, not a treatment you can get. It was tested on follicles in a dish, not on people, and no clinical trial results have been published. Below is what the study found, why it got attention, and where it fits among the hair-loss treatments that do exist.

From a transplant drug's side effect to a new target

Cyclosporine A (CsA) is an immunosuppressant that has been used since the early 1980s to stop the body rejecting transplanted organs, and later for some autoimmune conditions. It has a long list of side effects, from kidney strain to high blood pressure. One of the odder ones is hypertrichosis: excess hair growth on the face and body.

Because CsA is far too risky to take just for hair, researchers wanted to know how it switched follicles on, in the hope of finding a safer way to hit the same switch. The Manchester team, led by dermatologist Professor Ralf Paus, with Dr Nathan Hawkshaw as first author, set out to map what the drug was doing inside human hair follicles.

What the scientists actually did

The researchers used scalp follicles donated by men having hair transplant surgery. The university said follicles came from more than 40 patients across the project. The follicles were carefully dissected and kept alive in culture for up to six days, a method that lets scientists watch a hair shaft lengthen outside the body.

They treated follicles with CsA and then measured changes in gene activity. Among the genes examined, the strongest drop was in SFRP1, which makes a protein that dampens the Wnt/beta-catenin signalling pathway. Wnt signals are central to building and maintaining hair, and SFRP1 is produced mainly in the dermal papilla, the small cluster of cells at the base of the follicle that directs growth.

The team then added purified SFRP1 to follicles. It pushed them early into catagen, the phase where a hair stops growing and the follicle shrinks, and it cancelled the growth effect of CsA. That made SFRP1 look like a genuine brake.

Where WAY-316606 comes in

If SFRP1 is the brake, a drug that blocks it should work like CsA without suppressing the immune system. WAY-316606 was already known as an SFRP1 blocker from bone research, where boosting Wnt signalling helps build bone. In the follicle cultures it raised Wnt activity markers, increased hair shaft growth within two days, raised levels of a hair keratin, and held off the regression phase.

Hawkshaw described the result as exciting because of its "translational potential", meaning the chance to turn it into a real therapy, while stressing that a clinical trial was needed to show whether it is safe and effective in people.

Why it got so much attention

Hair loss is common and can be distressing. Male-pattern baldness (androgenetic alopecia) affects a large share of men as they age, and many women experience thinning too. Alopecia areata, an autoimmune condition that causes patchy or total hair loss, affects about 2% of people at some point in life.

The study also had a neat logic: it started with a known human effect and worked backwards to a target, rather than relying only on mice, whose hair cycles differ from ours. And the target, SFRP1, only amplifies Wnt signals that are already present. The authors suggested this might carry less risk than switching the pathway on everywhere, since uncontrolled Wnt activity is linked to some cancers. That idea was a hypothesis, not a tested result.

The limits of the research

  • Lab only. Follicles in a dish lack blood supply, hormones and immune cells, so they cannot show how a drug would behave in a living person.
  • Short and small. Cultures lasted days, not months, and most experiments used follicles from only a few donors, all men, all from the back of the scalp.
  • Unknown safety. WAY-316606 had not been approved for any use. Its long-term effects on skin, bone or other tissues in humans were not studied.
  • Funding. The work was funded by Giuliani, an Italian company that makes hair products, and the paper disclosed that link.

These are normal limits for early-stage research, but they explain why the headlines about a "cure for baldness" went too far.

Hair-loss treatments that do exist

In 2018 the university noted that only two medicines were widely used for male-pattern hair loss: minoxidil, applied to the scalp (and increasingly prescribed in low-dose tablet form), and finasteride, a tablet that reduces the hormone DHT. Both help many people, but results vary and stopping usually means the hair loss resumes. Hair transplant surgery moves follicles from the back of the head to thinning areas and can work well, but it is costly and invasive.

For alopecia areata, the picture has changed since the study. US regulators approved baricitinib in June 2022, ritlecitinib in June 2023 and deuruxolitinib in July 2024. All three are JAK inhibitors that calm the immune attack on follicles. They are not the same as the SFRP1 approach, and they carry their own risks, which is why they are prescribed and monitored by specialists.

Myths and practical takeaways

Myth: scientists found a cure for baldness. They found a mechanism and a candidate compound. Many promising lab results never become medicines.

Myth: you can buy WAY-316606 as a hair product. Some websites sell chemicals under this name, but there is no approved product and no evidence on safe use in people. Avoid self-experimenting with research chemicals.

Takeaway: hair loss has many causes, including genetics, autoimmune conditions, thyroid problems, iron deficiency, stress and some medicines. If you are worried, talk to a doctor or dermatologist, who can identify the cause and discuss proven options.

Sources: Hawkshaw et al., PLOS Biology, 8 May 2018; University of Manchester news release; Wikipedia: Alopecia areata; Sci.News, 10 May 2018; BBC News. Photo: Docent/Shutterstock.

COMMENTS